

Press Release

Abliva AB (publ), 556595-6538
04 May 2023 17:45:00 CEST - Lund,
Sweden



Amendment of the Nomination Committee's proposal for Abliva's Annual General Meeting in 2023

The notice for Abliva's Annual General Meeting (AGM) 2023 was announced in a press release on April 4th, 2023. The Nominating Committee's proposal for the election of Board members was presented in the press release. The Nomination Committee has now been informed that Dr. Edwin Moses is no longer available for re-election for personal reasons. David Laskow-Pooley has accepted re-election to the Board in addition to David Bejker, Jan Törnell, Denise Goode and Roger Franklin. The Nomination Committee proposes that David Laskow-Pooley is re-elected as Chair of the Board. The Nomination Committee also proposes a revised fee for the chairman of the board to be paid out at SEK 435,000 (400,000). Further, the Nomination Committee proposes a bonus payment in cash to David Laskow-Pooley of SEK 937,500. David Laskow-Pooley is required to use the full amount of the Bonus, net after income tax to acquire Abliva shares on the stock market. The company will pay the social security costs. The shares acquired for the Bonus will be locked in for a period of three (3) years after the acquisition.

"We are pleased that David Laskow-Pooley will continue in his position as Chairman of the Board of Abliva and look forward to his leadership as the company continues the Phase 2 FALCON study evaluating the efficacy of KL1333 in patients with primary mitochondrial disease," said Ingrid Teigland Akay, chair of the Nomination Committee.

Information about existing Board members can be found on the company's website www.abliva.com

For more information, please contact:

Catharina Johansson, Deputy CEO, CFO & VP Investor Relations
+46 (0)46-275 62 21, ir@abliva.com

Abliva AB (publ)

Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@abliva.com, www.abliva.com

Subscribe to our news: <https://abliva.com/posts/news-subscription/>
Follow us on LinkedIn: <https://www.linkedin.com/company/abliva>
Subscribe to our YouTube channel: <https://www.youtube.com/channel/UCChqP7Ky5caXtp72CELhD6Mg>

Press Release

Abliva AB (publ), 556595-6538
04 May 2023 17:45:00 CEST - Lund,
Sweden



Abliva – Delivering mitochondrial health

Abliva discovers and develops medicines for the treatment of mitochondrial diseases. These rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, is in clinical trials. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Attachments

[Amendment of the Nomination Committee's proposal for Abliva's Annual General Meeting in 2023](#)